Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Microbial Discovery Group LLC currently has 2 pending office actions in the Chemistry & Materials technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. BRAZIN, JACQUELINE is the busiest examiner, with 1 pending office action. This distribution indicates that each of the 2 pending actions is being handled by a different examiner in a different art unit.
Because there is no overlap between the 2 examiners or the 2 art units, the company cannot rely on a single unified strategy for its current pending matters. Each case must be handled according to the specific tendencies of the individual examiner and the standards of the respective art unit within the Chemistry & Materials field. This fragmentation suggests that the 2 pending actions may cover diverse technical aspects of the company's technology. Practitioners should monitor the feedback from both examiners to identify any potential conflicts in claim scope or interpretation across the portfolio. The outcome of these 2 pending office actions will provide a baseline for future filings in these specific art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAZIN, JACQUELINE | 1 | 65.6% | +52.7% |
| WILLIAMS, EMMALEE RAE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482000 | DIRECT FED MICROBIALS USING B. COAGULANS | WILLIAMS, EMMALEE RAE | 70d |
| 18682226 | MICROORGANISMS FOR TREATMENT OF HYDROCARBONS OR OIL | BRAZIN, JACQUELINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682226 | MICROORGANISMS FOR TREATMENT OF HYDROCARBONS OR OIL | BRAZIN, JACQUELINE | — |
| Art Unit | Apps |
|---|---|
| 1798 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682226 | MICROORGANISMS FOR TREATMENT OF HYDROCARBONS OR OIL | BRAZIN, JACQUELINE | 1798 | §102§103 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18482000 | DIRECT FED MICROBIALS USING B. COAGULANS | WILLIAMS, EMMALEE RAE | 1653 | §102DP | Final Rejection | 70d | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMicrobial Discovery Group LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jacqueline Brazin has the most, with 1 of Microbial Discovery Group LLC's pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
